Form 4: Inspire Medical Director Reports Inadvertent Trades

Inspire Medical Systems Director Myriam Curet reported inadvertent stock transactions, including a short-swing profit repayment of $4.97 to the company.

Summary

• Director Myriam Curet reported several transactions in Inspire Medical Systems, Inc. common stock.
• On March 20, 2025, 4 shares were acquired at $163.8388 per share.
• On April 7, 2025, 1 share was acquired at $148.262 per share.
• On May 8, 2025, 2 shares were disposed of at $153.2237 per share.
• On August 8, 2025, 4 shares were disposed of at $77.2754 per share.
• All transactions were stated to have occurred inadvertently through holdings in a pooled investment vehicle that did not filter out the Issuer's securities.
• A short-swing profit of $4.97, resulting from a purchase on April 7, 2025, and a sale on May 8, 2025, was paid to Inspire Medical Systems, Inc. by Dr. Curet to comply with Section 16(b) of the Securities Exchange Act of 1934.
• Following these transactions, Myriam Curet beneficially owns 3,365 shares of common stock directly.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the occurrence of inadvertent transactions and a Section 16(b) violation, even though the profit was repaid. This indicates a lapse in compliance oversight for the director's investment vehicle, though the prompt repayment mitigates the severity.

Positives

• The reporting person promptly identified and rectified a Section 16(b) violation by repaying the short-swing profit to the company.

Negatives

• Inadvertent transactions occurred due to a failure in a pooled investment vehicle to filter out the issuer's securities.
• A Section 16(b) short-swing profit violation occurred, requiring the director to repay $4.97 to the company.

Risks

• Potential for future inadvertent transactions if the pooled investment vehicle's filtering mechanism is not fully rectified.
• Reputational risk for the director due to the compliance violation, even if inadvertent.

Future Outlook

NA

Management Comments

• These transactions occurred inadvertently through holdings in a pooled investment vehicle that did not filter out the Issuer's securities.
• The Reporting Person's sale of common stock on May 8, 2025 were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 1 share at a price per share of $153.2237, with the Reporting Person's purchase of 1 share of common stock at a price per share of $148.262 on April 7, 2025.
• Dr. Curet paid to the Issuer $4.97, representing the full amount of the profit realized in connection with the short-swing transaction.

Industry Context

This filing is specific to an individual insider's transactions and does not provide broader industry context or trends.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• The reporting person was subject to Section 16(b) of the Securities Exchange Act of 1934, which required the repayment of a short-swing profit to the issuer. This is a regulatory compliance matter rather than a formal legal proceeding.

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Minimal direct financial impact due to the small amount of profit repaid. However, it highlights the importance of insider compliance.
• Company: Received a minor repayment of $4.97. The incident underscores the need for clear communication and robust compliance procedures for directors regarding their personal investments.

Next Steps

• The reporting person or their pooled investment vehicle should implement stricter controls to prevent future inadvertent transactions in the issuer's securities.

Key Dates

Recommendation

This Form 4 filing details inadvertent insider transactions and a minor Section 16(b) violation that was promptly rectified by the director. The financial impact is negligible ($4.97 repayment), and the incident does not reflect on the company's operational performance or strategic direction. It's a compliance matter for an individual director, not a fundamental change in the company's prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Inspire Medical Systems, INSP, Form 4, Insider Trading, Myriam Curet, Director, Stock Transactions, Section 16(b), Short-Swing Profit, Compliance, Equity Securities